Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial

doi:10.4239/wjd.v17.i3.114002

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (61)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-8) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-8)

Sum=61

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=12

Mar 15, 2026 (publication date) through Mar 15, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Mar 15, 2026; 17(3): 114002
Published online Mar 15, 2026. doi: 10.4239/wjd.v17.i3.114002

Open in New Tab Full Size Figure Download Figure

Figure 1 The pharmacological mechanism of compound danshen dripping pill in the treatment in diabetic retinopathy. tPA: Tissue type plasminogen activator; PAI: Photoacoustic imaging; FIB: Fibrinogen; HsCRP: Hypersensitive c-reactive protein; MCP: Monocyte chemotactic protein; TNF-α: Tumor necrosis factor- alpha; TC: Total cholesterol; LDL-C: Low density lipoprotein cholesterol; GSH-Px: Glutathione peroxidase; MDA: Malondialdehyde.

Open in New Tab Full Size Figure Download Figure

Figure 2 Study flowchart. CDDP: Compound danshen dripping pill.

Open in New Tab Full Size Figure Download Figure

Figure 3 Changes in the severity of retinal microangiopathy. CDDP: Compound danshen dripping pill.

Citation: An XD, Zhang GL, Zhang YH, Jin D, Ji HY, Wei LJ, He YL, Zheng YL, Li DJ, Wu XW, Li YB, Zhou J, Tan SJ, Zhang MC, Fan K, Lu S, Yu JS, Wang YL, Chen SJ, Liu QH, Jin M, Wu L, Lian FM, Tong XL. Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial. World J Diabetes 2026; 17(3): 114002
URL: https://www.wjgnet.com/1948-9358/full/v17/i3/114002.htm
DOI: https://dx.doi.org/10.4239/wjd.v17.i3.114002

An XD, Zhang GL, Zhang YH, Jin D, Ji HY, Wei LJ, He YL, Zheng YL, Li DJ, Wu XW, Li YB, Zhou J, Tan SJ, Zhang MC, Fan K, Lu S, Yu JS, Wang YL, Chen SJ, Liu QH, Jin M, Wu L, Lian FM, Tong XL. Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial. World J Diabetes 2026; 17(3): 114002 [DOI: 10.4239/wjd.v17.i3.114002]

©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA